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 Systemic inflammation is a hallmark of cancer patients, the 
inflammatory response being the main driving force behind the 
metabolic alterations present in the cancer patient. 
 Chemotherapy exacerbates cancer cachexia. Some chemotherapeutic 
agents induce both pro-cachectic cytokines and myostatin. 
 The elucidation of the interactions between all the mediators involved 
in cancer cachexia –cytokines, chemokines, tumour factors, myostatin-
- may possibly accelerate the development of novel therapeutic 
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Alterations in amino acid and protein metabolism --particularly in skeletal 
muscle-- are a key feature of cancer patients that contribute to the cachexia 
syndrome. Thus, skeletal muscle protein turnover is characterized by an 
exacerbated rate of protein degradation, promoted by an activation of different 
proteolytic systems that include the ubiquitin-proteasome and the autophagic-
lysosomal pathways. These changes are promoted by both hormonal 
alterations and inflammatory mediators released as a result of the systemic 
inflammatory response induced by the tumour. Other events, such as 
alterations in the rate of myogenesis/apoptosis and decreased regeneration 
potential also affect skeletal muscle in cancer patients. Mitochondrial 
dysfunction also contributes to changes in skeletal muscle metabolism and 
further contributes to the exacerbation of the cancer-wasting syndrome. 
Different inflammatory mediators --either released by the tumour or by healthy 
cells of the cancer patient— are responsible for the activation of these 
catabolic processes that take place in skeletal muscle and in other 
tissues/organs, such as liver or adipose tissues. Indeed, white adipose tissue 
is also subject to extensive wasting and "browning" of some of the white 
adipocytes into beige cells, therefore increasing the energetic inefficiency of 
the cancer patient. Recently, an interest in the role of micro-mRNAs --either 
free or transported into exosomes-- has been related with the events that take 
place in white adipose tissue during cancer cachexia. 





Cancer is an inflammatory state 
 
 
Cancer is an inflammatory disease[1]. Indeed, systemic inflammation is a 
hallmark of cancer patients[2]. In fact, the inflammatory response is the main 
driving force behind the metabolic alterations present in the cancer patient. 
The origin of the inflammation is multiple: on one hand tumour cells may 
themselves release cytokines and other inflammatory mediators; on the other 
hand activated immune cells release cytokines and chemokines. Both the 
tumour and the gut mediate the activation of the immune cells. Indeed, gut 













Thus, the release of LPS and other bacterial toxins activates cytokine 
synthesis and release by immune cells. Cytokines promote the activation of 
transcription factors associated with wasting, both in adipose tissue and 
skeletal muscle, therefore leading to wasting[4]. In addition to inflammatory 
mediators, other molecules also contribute to the metabolic abnormalities 
present in the cancer patient. Tumour-derived factors, other than cytokines, 
have been proposed as triggers of the wasting process associated with cancer 
cachexia. Two of these molecules, lipid mobilizing factor (LMF) and the 
proteolysis-inducing factor (PIF) have been found in tumour-bearing animals 
and cancer patients[5]. Another interesting molecule associated with muscle 
wasting is myostatin. This protein is a transforming growth factor β (TGFβ) 
ligand, which operates through activin receptor type II B (ActRIIB)-mediated 
signalling[6]. Myostatin is involved in skeletal muscle wasting in different 
catabolic conditions, including cancer[7]. In fact, inactivation of myostatin and 
other TGFβ family of proteins by treatment with sActRIIB (a soluble form of 
ActRIIB) ablates the symptoms of cancer cachexia in tumour-bearing 
mice[8,9]. In fact, we now know that myostatin may be released not only by 
tissues such as skeletal muscle and adipose tissue (to a lesser extent) but 
also by cachexia-inducing tumours[10]. Interestingly, TGF- also participates 
in the bone-muscle crosstalk and seems to be a cause of skeletal muscle 
weakness in the setting of osteolytic cancer in the bone[11]. 
 
It is clear that the elucidation of the interactions between all the mentioned 
molecules –cytokines, chemokines, tumour factors, myostatin-- may possibly 
accelerate the development of novel therapeutic interventions against cancer -
induced inflammation and thus, cachexia. 
 




 Different altered metabolic pathways contribute to muscle wasting during 
cachexia[12]. Thus, skeletal muscle protein turnover is characterized by an 
exacerbated rate of protein degradation promoted by an activation of different 
proteolytic systems that include the ubiquitin-proteasome and the autophagic-
lysosomal pathways[13]. Changes in the rate of myogenesis/apoptosis also 













decreased skeletal muscle regeneration capacity is observed together with an 
increased rate of cell death, resulting in muscle wasting[15,16]. Mitochondrial 
dysfunction also results in changes in skeletal muscle metabolism and further 
contributes to the exacerbation of the cancer-wasting syndrome[17].  
 
Inflammatory cytokines contribute to the activation of proteolysis. However, 
tumour-derived factors have also been involved[18]. The cytokines involved in 
muscle wasting during cancer, Tumour necrosis factor- (TNF-, TNF-like 
weak inducer of apoptosis, (TWEAK), Tumour necrosis factor receptor 
(TNFR), -associated factor 6 (TRAF6), Interleukin-6 (IL-6), gamma-Interferon 
(-IFN) and Leukaemia Inhibitory Factor (LIF)[19,20] act via two different 
intracellular pathways: the NF-kappaB and the p38 MAP kinase pathways. 
They are both involved in the up regulation of the expression of E3 ligases 
MuRF-1 and MAFbx. Inhibition of NF-kappaB, at least in rodents, results in a 
decreased muscle loss in tumour-bearing animals[21]. This pathway acts 
partly by activating the formation of NO --through induction of the iNOS—
therefore increasing nitrosative stress[22] which can also activate protein 
degradation in skeletal muscle. These cytokines also activate the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway. 
During cancer, there is an induction of STAT3 phosphorylation in skeletal 
muscle[23]. However, interestingly, STAT3 also seems to have a role in 
autophagy resulting in an alteration of the beclin complex and, therefore, 
blocking autophagy and stopping muscle degeneration[24]. In particular, LIF --
a cytokine that can also be released by some tumours-- is also involved in 
promoting adipose tissue dissolution by activating lipolysis[25]. 
 
According to White et al. IL-6 suppression of mTOR activity is dependent on 
AMP kinase (AMPK) activation and independent of STAT signalling in 
myotubes[26]. AMPK ? is able to phosphorylate FOXO, therefore, stimulating 
its transcriptional activity (26). AMPK is also able to activate autophagy genes 
[27]. 
 
Sun et al. found a positive correlation between TRAF6 and ubiquitin 
expression in skeletal muscle of gastric cancer patients, suggesting that 
TRAF6 may up-regulate ubiquitin activity in cancer cachexia[28]. On the same 
lines, TWEAK, a cytokine belonging to the TNF- family, is able to induce a 













also able to induce the autophagy system in skeletal muscle cells and this 
seems to be dependent on NF-kappaB activation[29]. Furthermore, caspases 
seem to contribute, at least in part, to the activation of NF-kappaB in response 
to TWEAK treatment[29]. The cytosolic release of its inhibitory IkappaB 
proteins allows the translocation of NF-kappaB to the nucleus and subsequent 
transcription of genes involved in proteolysis. Inhibition of NF-kappaB 
decreases muscle loss in a rat model of cancer cachexia, in part, by inhibiting 
the up regulation of MuRF-1[30]. 
 
Mitochondrial dysfunction is present in skeletal muscle during cancer 
cachexia. Indeed, distorted mitochondria are present in muscle during cancer 
cachexia[31], this being associated with loss of skeletal muscle structural 
integrity. In these mitochondria, ATP synthesis is decreased[31] and oxidative 
phosphorylation uncoupling is present[32]. Free radical species --superoxide, 
hydroxyl radicals, nitric oxide, peroxynitrite and hydrogen peroxide-- play a key 
role in modulating inflammation-driven alterations in skeletal muscle function, 
particularly in mitochondria[22]. Indeed, free radicals have important effects on 
sarcoplasmic reticulum, mitochondrial function and sarcolemmal integrity. 
Sarcoplasmic reticulum and mitochondria act in very close collaboration in the 
process of muscle contraction. Precisely, alterations in some of the proteins 
participating in this "tandem" --such as mitofusin-- have been described in 
experimental cancer cachexia[33]. Cytokines, TNF- in particular, are 
associated with increased oxidative stress in skeletal muscle during cancer. In 
fact, the TNF--1031T/C polymorphism seems to be a marker of cachexia risk 
in head and neck cancer patients[34]. Padrao et al. using a bladder cancer rat 
model of muscle wasting, concluded that mitochondrial dysfunction was 
associated with an accumulation of both oxidized and nitrated proteins which 
could not be repaired by mitochondrial proteases and the mitochondrial 
shaping machinery[35]. This enzymatic machinery is responsible for 
maintaining the cellular redox state by removing oxidized or misfolded 
proteins[36]. Interestingly, many cytokines activate the transcriptional PGC-1, 
through phosphorylation by p38 kinase, resulting in stabilization and activation 
of PGC-1[36].
linked to mitochondrial uncoupling and energy expenditure[36]. White et al. 
(49) clearly demonstrated a role for IL-6 in the skeletal muscle mitochondrial 













model --this contains the adenomatous polyposis coli (APC) gene required to 
initiate familial adenomatous polyposis (FAP)-- repressed expression of PGC-
1 and mitofusin 1&2 --related to mitochondrial fission in skeletal muscle— 
were found while FIS1 expression --related with mitochondrial fission-- was 
increased[38]. All of these changes were linked to alterations in mitochondrial 
morphology and decreased mitochondrial content and decreased complex IV 
and cytochrome C proteins[39]. Interestingly in the ApcMin/+ mouse model, IL-6 
is necessary to induce muscle wasting and overexpression of the cytokine in 
precachectic ApcMin/+ mice activates the development of cachexia[38]. 
Administration of IL-6 antibody to ApcMin/+ mice was able to restore the 
alterations associated with abnormal mitochondrial function -- increased PGC-
1, complex IV and cytochrome C proteins and improved mitochondrial 
content[37]. The same authors demonstrated direct effects on mitochondrial 
parameters of IL-6 on isolated muscle cells suggesting that the cytokine 
mediates directly mitochondrial muscle alterations[37].  
 
Another interesting cytokine is Interleukin-8 (IL-8). Indeed, elevated serum 
levels of the cytokine correlate with cancer-related cachexia[40]. In pancreatic 
cancer IL-8 is an indicator of cancer outcomes[40]. The genetic polymorphism 
of this myokine can contribute to the pathogenesis of cachexia in gastric 
cancer[41]. Another molecule that has been shown to be a possible biomarker 
of cancer cachexia is monocyte chemo attractant protein-1: (MCP-1) is 
associated with cachexia in cancer patients[42].  
 
Wang et al. have recently identified the metal-ion transporter ZIP-14 as a 
critical mediator in cancer cachexia[43]. Indeed, the transporter is up regulated 
in skeletal muscle of both cancer patients and in tumour-bearing animals. The 
protein is induced by cytokines, TNF- and TGF-. This suggests a role for 
altered zinc homeostasis in cachectic cancer patients.  
 
Concerning tumour factors, the so-called proteolysis-inducing factor (PIF) was 
identified as a circulating tumour-released mediator in mice bearing a 
cachexia-inducing (MAC16)[44]. Moreover, human tumours also express the 
so-called PIF[44]. This molecule --a 24kDa glycoprotein-- causes weight loss 
by inducing enhanced protein degradation without decreasing the appetite in 
mice. PIF was also found to be present in the urine of cachectic cancer 













has been highly debated[46]. In addition, the lipid mobilizing factor zinc-α2-
glycoprotein (ZAG) actively participates in the dissolution of adipose tissue by 
activating lipolysis[5]. 
 
It has to be pointed out that some cytokines (IL-4, IL-10) can actually act as 
anti-cachectic[47]. One of them, IL-15, has been shown to have a clear anti-
proteolytic[48–50] and antiapoptotic action in skeletal muscle of animals under 
cancer cachexia[51]. 
 
The role of exosomes 
 
Extracellular vesicles (EVs), including exosomes and microvesicles, are 
nanovesicles involved in cellular communication, immune response, tissue 
repair, epigenetic regulation, and in various diseases including cancer. In 
cancer these EVs regulate progression, metastasis and chemoresistance. 
Exosomes, measuring from 30 to 100 µm, can act in an autocrine, paracrine, 
and endocrine manner. Recently, an interest in the role of EVs in regulating 
cancer cachexia has emerged. Zhang et al. reported extracellular heat-shock 
proteins --either released in soluble form or in exosomes--, Hsp 70 and Hsp90, 
to be responsible for induction of cancer cachexia in mice[52]. These proteins 
can also be related with the secretion of pro-cachectic cytokines together with 
the activation of Toll-like receptor4 (TLR4) in skeletal muscle[53]. Interestingly, 
Henriques et al. have shown that genetic ablation and pharmacological – 
Atorvastatin-- inhibition of TLR4 were able to attenuate the main clinical 
markers of cachexia in mice bearing Lewis lung carcinoma (LLC)[54]. 
Moreover, the treatment was effective in prolonging survival and attenuating 
tumour mass growth when compared to non-treated-tumour-bearing animals. 
 
Chemotherapy exacerbates cancer cachexia 
 
 
Cancer chemotherapeutic treatment often contributes to body weight loss and 
cachexia [55]. For instance, platinum-based cancer treatment induces weight 
loss, fatigue and inflammation in cancer patients[56]. It seems that this type of 
treatment induces both pro-cachectic cytokines and myostatin[56]. 
Interestingly recent work[57] has shown that Cachexia induced by the tumour 
and chemotherapy give rise to distinct alterations in energy metabolism. 













characterized by a number of distinct metabolic derangements, indicating that 
effective therapeutic treatments for cancer-induced and chemotherapy-
induced cachexia must take into account the specific metabolic alterations 
induced by the pathological or pharmacological mediators of cachexia. 
Chemotherapeutic treatment affects skeletal muscle in cancer patients 
through effects of the drugs on mitochondrial content and/or ROS 
production[58]. 
 
Adipokines and adipose tissue browning 
 
 
Cancer cachexia is a multi-organ syndrome involving different organs/tissues. 
Therefore, muscle wasting occurs together with alterations in other target 
tissues. Following suit, adipose tissue is also under huge wasting. 
Metabolically, in addition to massive lipolysis, decreased lipogenesis from 
glucose and impaired entry of fatty acids owing to decreased activity of 
lipoprotein lipase (LPL) contribute to adipose tissue wasting. In addition, a 
clear interplay of adipokines and myokines in cancer exists, therefore, 
supporting the importance of inter-organ signalling between skeletal muscle 
and adipose tissue[59,60]. Apart from these metabolic alterations that lead to 
adipose tissue dissolution, in cancer cachexia, white adipose cells acquire 
some of the molecular machinery that characterizes brown adipose cells. This 
represents a ‘browning’ of white cells, in which uncoupling protein 1 (UCP1) is 
expressed and promotes uncoupling and, consequently, heat production and 
energetic inefficiency. This cell conversion can be triggered by both humoral 
inflammatory mediators, such as interleukin-6 (IL-6)[59,61], and tumour-
derived compounds, such as parathyroid-hormone-related protein 
(PTHRP)[62]. In addition, the lipid mobilizing factor zinc-α2-glycoprotein (ZAG) 
--a protein secreted by some tumours[5]-- not only induces lipolysis in adipose 
tissues but also causes robust browning in WAT[63]. 
 
As previously mentioned, exosomal circRNA derived from gastric tumour 
promotes white adipose browning by targeting the miR-133/PRDM16 pathway. 
Interestingly, inhibiting exosome generation and release can inhibit lipolysis 
and adipose tissue browning, and may be useful as a novel strategy for 














The understanding of adipose tissue dysfunction in cancer cachexia will 
hopefully promote the development of new therapeutic approaches to prevent 






In cancer patients, functional alterations within brain areas controlling energy 
homeostasis contribute to the onset of anorexia, reduced food intake, and 
increased catabolism in both muscle and adipose tissue. Increases in 
proinflammatory cytokines, suggest neuroinflammation as an adaptation to 
tumour growth. In particular, the vagus nerve appears to be involved in 
conveying input signals to the hypothalamus, whereas hypothalamic serotonin 
appears to contribute to triggering catabolic signals[65]. The area postrema 
(AP) and the nucleus tractus solitarii are two important brainstem centres for 
the control of eating during acute sickness conditions. Recently, the tumour-
derived macrophage inhibitory cytokine-1 (MIC-1) emerged as a possible 
mediator of cancer anorexia because lesions of these brainstem areas 
attenuated the anorectic effect of exogenous MIC-1 in mice[42,66]. Therefore, 
the AP seems to have a very important role in the cancer-induced anorexia 
and body weight loss suggesting a role of MIC-1 as a tumour-derived factor in 
cancer anorexia, via an AP-dependent action. 
 
Indeed, hypothalamic inflammation contributes to muscle and adipose tissue 
loss in cancer via hypothalamic IL1β-induced activation of the hypothalamic-
pituitary-adrenal axis[67]. As a result glucocorticoids are released directly 
activating skeletal muscle protein catabolism through activation of the 
ubiquitin-dependent proteolytic system. In addition, hypothalamic inflammation 
in cancer results in a decrease in food intake in cancer by promoting changes 
in orexigenic and anorexigenic mediators via up regulation of serotonin 
availability and stimulation of its signalling pathways in hypothalamic tissues. 
Both reduced food intake and stimulation of tissue catabolism represents a 
dual mechanism by which hypothalamic inflammation contributes to the 
development and maintenance of anorexia and cachexia in cancer[67]. 
 
Hypothalamic activity in anorectic cancer patients is decreased as compared 













suggests a central control of appetite dysregulation during cancer anorexia, 
before, and after oral intake[65]. 
 
 
The role of microRNAs 
 
Exosomes containing microRNAs (miRNAs) and muscle-specific miRNAs 
(myomiRs) constitute a mechanism recently reported to be involved in cancer 
cachexia[68]. miRNAs transported in exosomes transport and preserve 
miRNAs from degradation, delivering the miRNAs to specific cell targets, 
making communication more efficient. Several miRNAs are known to 
modulate inflammatory pathways, to induce metastasis, to mediate cancer 
aggressiveness and even to participate in the regulation of beige/brown 
adipocytes differentiation. Thus breast cancer-released exosomes contained 
miR-155 which promotes adipocyte browning by down regulating PPARg 
expression[69,70]. Circular RNAs (circRNAs) are a novel family of 
endogenous noncoding RNAs that have been proposed to regulate gene 
expression in mammals. These RNAs are stable in exosomes. However, little 
is known about the biological role of circRNAs in exosomes. Zhang et al. 
showed that circRNAs in plasma exosomes have specific expression features 
in gastric cancer (GC), and ciRS-133 is linked with the browning of white 
adipose tissue (WAT) in GC patients[71]. 
 
 
Using anti-inflammatory therapeutic strategies  
 
Blocking the inflammatory response may have positive effects on muscle 
wasting. Due to the multifactorial aspects of cachexia syndrome, any 
therapeutic approach based on increasing food intake has to be combined 
with a nutritional/pharmacological strategy to counteract the inflammatory 
response and prevent skeletal muscle metabolic changes. A clear research 
direction is, therefore, the identification of biological, immunological, chemical, 
genetic or behavioural non-invasive markers to be used. These markers, in 
addition to their utility to detect pre-cachectic subjects that will eventually 
suffer the full syndrome, may serve as an index of successful outcome 
measures in cachexia or the treatment and management of the syndrome. 
Additional future directions in the field should contemplate the role of the 
neuroendocrine system in the development of cachexia, the determination of 













interventions and which symptoms require behavioural interventions in order 
to improve quality of life of the patients and finally to explore regimens (e.g., 
physical activity and nutrient supplementation) to improve dyspnoea, impaired 
mobility, pain, anorexia and fatigue associated with cachexia. On the lines 
physical activity seems to be an element to decrease inflammation[72–74], 
however there is insufficient evidence to determine safety and effectiveness in 
patients with cancer cachexia. Findings from on-going studies are awaited. 
Assessment of cachexia domains, ideally against international criteria, is 
required for future trials of exercise and supportive care interventions[75]. 
 
In conclusion, although both tumoural and humoural (mainly cytokines) factors 
that trigger cachexia may share common signalling pathways, therefore, it is 
not very likely that a single drug will block the complex processes involved in 
cachexia. In addition, some of the mediators proposed for the wasting 
syndrome also play a role in the regulation of body weight in absolutely 
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